V R Bollela1, E I Namburete1, C S Feliciano1, D Macheque2, L H Harrison3, J A Caminero4. 1. Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil. 2. Laboratório Nacional de Referencia da Tuberculose, Instituto Nacional de Saúde-Moçambique, Maputo, Mozambique. 3. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 4. Servicio de Neumología, Hospital General de Gran Canaria Dr Negrin, Las Palmas, Spain; International Union Against Tuberculosis and Lung Disease, Paris, France.
Abstract
BACKGROUND: Depending on the presence of mutations that determine isoniazid (INH) susceptibility (katG and inhA), Mycobacterium tuberculosis may be susceptible to high doses of INH or ethionamide (ETH). OBJECTIVE: To describe the INH resistance profile and association of katG mutation with previous INH treatment and level of drug resistance based on rapid molecular drug susceptibility testing (DST) in southern Brazil and central Mozambique. DESIGN: Descriptive study of 311 isolates from Ribeirão Preto, São Paulo, Brazil (2011-2014) and 155 isolates from Beira, Mozambique (2014-2015). Drug resistance patterns and specific gene mutations were determined using GenoType(®) MTBDRplus. RESULTS: katG gene mutations were detected in 12/22 (54.5%) Brazilian and 32/38 (84.2%) Mozambican isolates. inhA mutations were observed in 9/22 (40.9%) isolates in Brazil and in 4/38 (10.5%) in Mozambique. Both katG and inhA mutations were detected in respectively 1/22 (5%) and 2/38 (5.2%). The difference in the frequency of katG mutations in Brazil and Mozambique was statistically significant (P = 0.04). katG mutations were present in 68.8% (33/48) of patients previously treated with INH and 31.2% (15/48) of patients without previous INH. This difference was not statistically significant (P = 0.223). CONCLUSION: INH mutations varied geographically; molecular DST can be used to guide and accelerate decision making in the use of ETH or high doses of INH.
BACKGROUND: Depending on the presence of mutations that determine isoniazid (INH) susceptibility (katG and inhA), Mycobacterium tuberculosis may be susceptible to high doses of INH or ethionamide (ETH). OBJECTIVE: To describe the INH resistance profile and association of katG mutation with previous INH treatment and level of drug resistance based on rapid molecular drug susceptibility testing (DST) in southern Brazil and central Mozambique. DESIGN: Descriptive study of 311 isolates from Ribeirão Preto, São Paulo, Brazil (2011-2014) and 155 isolates from Beira, Mozambique (2014-2015). Drug resistance patterns and specific gene mutations were determined using GenoType(®) MTBDRplus. RESULTS: katG gene mutations were detected in 12/22 (54.5%) Brazilian and 32/38 (84.2%) Mozambican isolates. inhA mutations were observed in 9/22 (40.9%) isolates in Brazil and in 4/38 (10.5%) in Mozambique. Both katG and inhA mutations were detected in respectively 1/22 (5%) and 2/38 (5.2%). The difference in the frequency of katG mutations in Brazil and Mozambique was statistically significant (P = 0.04). katG mutations were present in 68.8% (33/48) of patients previously treated with INH and 31.2% (15/48) of patients without previous INH. This difference was not statistically significant (P = 0.223). CONCLUSION: INH mutations varied geographically; molecular DST can be used to guide and accelerate decision making in the use of ETH or high doses of INH.
Authors: A Van Rie ; R Warren; I Mshanga; A M Jordaan; G D van der Spuy ; M Richardson; J Simpson; R P Gie; D A Enarson; N Beyers; P D van Helden ; T C Victor Journal: J Clin Microbiol Date: 2001-02 Impact factor: 5.948
Authors: Paulo F Perizzolo; Elis R Dalla Costa; Andrezza W Ribeiro; Fernanda S Spies; Marta O Ribeiro; Cláudia F Dias; Gisela Unis; Pedro Almeida da Silva; Harrison M Gomes; Philip N Suffys; Maria Lucia R Rossetti Journal: Tuberculosis (Edinb) Date: 2011-10-15 Impact factor: 3.131
Authors: A R Baulard; J C Betts; J Engohang-Ndong; S Quan; R A McAdam; P J Brennan; C Locht; G S Besra Journal: J Biol Chem Date: 2000-09-08 Impact factor: 5.157
Authors: Margaretha de Vos; Brigitta Derendinger; Tania Dolby; John Simpson; Paul D van Helden; John E Rice; Lawrence J Wangh; Grant Theron; Robin M Warren Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Alexander V Kukhtin; Ryan Norville; Arial Bueno; Peter Qu; Nicole Parrish; Megan Murray; Darrell P Chandler; Rebecca C Holmberg; Christopher G Cooney Journal: Anal Chem Date: 2020-03-24 Impact factor: 6.986
Authors: Pauline Lempens; Conor J Meehan; Koen Vandelannoote; Kristina Fissette; Pim de Rijk; Armand Van Deun; Leen Rigouts; Bouke C de Jong Journal: Sci Rep Date: 2018-02-19 Impact factor: 4.379